Navigation Links
Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
Date:6/2/2009

NIH funds human clinical testing of the cell trafficking MRI reagent, Cell Sense.

Pittsburgh, PA (Vocus) June 2, 2009 -- Celsense, Inc. announced today that it is one of the recipients in a 4-year $1.95M grant from the National Institutes of Health. The funded studies will be the first effort to evaluate Cell Sense, the Company’s fluorocarbon-based magnetic resonance imaging (MRI) cell tracking reagent, for clinical use. Additionally, the studies will garner preliminary data critically important for improving immunotherapeutic delivery strategies in metastatic colorectal (CRC) and other forms of cancer.

The Cell Sense technology makes transplanted cells visible by MRI. Therapeutic cells are labeled ex vivo with the Cell Sense reagent prior to administration to the patient. Cell migration and biodistribution are subsequently monitored using fluorine-19 (19F) MRI or magnetic resonance spectroscopy (MRS). The key advantage of Cell Sense is that the 19F images are extremely selective for the labeled cells, with no background signal from the host’s tissues. Furthermore, accurate cell quantification in regions of interest is possible.

Existing data from pre-clinical studies using human cells show that the Cell Sense reagent is highly biocompatible inside cells and does not affect their innate function. A clinical-grade version of the Cell Sense reagent has been formulated by Celsense, Inc. and is currently being subjected to mandatory in vitro and animal safety studies in preparation for human trials.

To conduct this project, Celsense has partnered with academia, including scientists at Carnegie Mellon University, where the imaging technology was invented in the laboratory of Dr. Ahrens. Also participating is the University of Pittsburgh Cancer Institute (UPCI) which is actively conducting clinical trials using immunotherapeutic dendritic cell (DC) vaccines to treat CRC, directed by Drs. Kalinski and Bartlett.

About Colorectal Cancer (CRC)
CRC is the third leading cancer in the United States and the most common form of gastrointestinal malignancy. CRC accounts for approximately 150,000 new cases annually. Immunotherapeutic interventions using live-cell DC vaccines may potentially be effective in CRC patients. To date, the inability to accurately follow the location of the cells after transfer to the patient is one of the critical bottlenecks in the development and delivery of cancer immunotherapies.

About Cell Sense
Cell Sense (patent-pending) is a fluorocarbon tracer agent used to safely and efficiently label cells ex vivo without the use of transfection agents. Labeled cells are transplanted into the patient enabling researchers and clinicians to non-invasively track the administration and migration of therapeutic and/or diagnostic cells using 19F MRI or MRS. Applications include tracking cells in immunotherapy or regenerative medicine as well as diagnosis of inflammatory sites by tracking selected populations of immune cells. Using software developed by Celsense, investigators can quantify the number of labeled cells in a user-specified region of interest. It is expected that in vivo cellular imaging will routinely be used to provide a surrogate biomarker for certain cellular therapeutic and drug trials.

About Celsense, Inc.
Celsense, Inc. is a biotechnology company offering novel pre-clinical and clinical-grade cellular and molecular imaging agents used to non-invasively monitor biological processes in living systems. The core innovations of the Company involve proprietary imaging agents that can be used to observe the trafficking of cells using magnetic resonance techniques. Celsense’s mission is to be the standard for cellular imaging in human health. For more information, see Celsense.com.

Information Contact: Charlie O’Hanlon, President and CEO of Celsense, Inc.

###

Read the full story at http://www.prweb.com/releases/Celsense/2009-6-1/prweb2483234.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
2. 500th Patient Receives Berlin Heart EXCOR Pediatric Ventricular Assist Device
3. SyntheMed Receives Australian Regulatory Approval for REPEL-CV(R)
4. Astellas Receives FDA Approval for Use of Prograf(R) (Tacrolimus) in Conjunction With Mycophenolate Mofetil (MMF) in Kidney Transplant Recipients
5. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
6. Genaera Receives Non-Compliance Notice from Nasdaq
7. AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
8. Catalyst Pharmaceutical Partners Receives NASDAQ Deficiency Notice
9. NeurogesX Receives European Commission Approval for Qutenza(TM)
10. deCODE Genotyping Laboratory Receives College of American Pathologists Accreditation
11. GenVault Receives Four Critical U.S. and E.U. Patent Allowances for Key Biosample Management Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Celsense, Inc Receives NIH Grant to Translate Cell Imaging Technology for Clinical Use
(Date:6/23/2016)... ... , ... Supplyframe, the Industry Network for electronics hardware design ... Located in Pasadena, Calif., the Design Lab’s mission is to bring together inventors ... and brought to market. , The Design Lab is Supplyframe’s physical representation of ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... , June 23, 2016 On Wednesday, ... at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged ... closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on ... ), Nektar Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals ... (NASDAQ: BIND ). Learn more about these stocks ...
Breaking Biology Technology:
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/21/2016)... 2016 Unique technology combines ... superior security   Xura, Inc. ... secure digital communications services, today announced it is working ... enterprise customers, particularly those in the Financial Services Sector, ... authentication within a mobile app, alongside, and in combination ...
Breaking Biology News(10 mins):